NCT06414902View on ClinicalTrials.gov

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2027

Conditions

Esophageal Cancer

Interventions

DRUG

ArabinoFuranosylGuanine [18F]F-AraG

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER